Abstract Details

Title Patient Support Program Enhancements In Patients Diagnosed With Generalized Myasthenia Gravis Facing Social Determinants of Health Challenges

Topic Health Care Disparities

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 4-006

Objective To better understand the needs of patients living with generalized Myasthenia Gravis (gMG) and impacted by Social Determinants of Health (SDOH) challenges in terms of Patient Support Program (PSP) services to improve patient outcomes.

Background SDOH challenges are factors of the environment or patients’ lives that affect health, functioning, and quality of life outcomes.

Design/Methods Phase One – Qualitative research was conducted with 11 patients and 2 Patient Advocacy Groups (PAGs) to understand PSP awareness, experience, and unmet needs. Phase Two – Quantitative research was conducted with 38 patients, the majority were people of color, non-urban residents and low-income women. We identified SDOH challenges, assessed current utilization of services and unmet needs for PSP services to be addressed through new offerings. Phase three – Qualitative research was conducted with 11 Health Care Professionals (HCPs) to understand how they address SDOH challenges in treating patients with gMG.

Results In Phase Two, four prioritized PSP solutions were identified: 1) Expand current PSP services, including a medication information hotline, symptom tracking app, and updated educational resources; 2) Develop a personalized "human touch", e.g., 1:1 patient mentoring program for people initiating treatment or experiencing medical complications; 3) Create an innovative giving strategy and establish a long-term financial commitment to support patients living with gMG, 4) Increase PAGs awareness of Nurse Case Manager services. In Phase Three, we found most HCPs are not adequately trained to identify patients with SDOH challenges, have limited training on educating patients on gMG, and often depend on social workers and nurses for these tasks.

Conclusions For patients living with gMG encountering SDOH challenges, there are opportunities to bolster PSP offerings to improve patient outcomes. HCPs receive limited training on educating patients about potential solutions to SDOH challenges.

Authors/Disclosures
Tom Hughes, PhD (Argenex) PRESENTER	Dr. Hughes has received personal compensation for serving as an employee of Argenx . Dr. Hughes has stock in argenx.
	No disclosure on file
Ashley E. Anderson, MD (Houston Methodist - Department of Neurology)	Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/Johnson&Johnson. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Anderson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen.
Ali A. Habib, MD (University of California, Irvine)	Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for argenx. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NMD Pharma. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/ Amgen. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kyverna. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jansen/Johnson & Johnson. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMDSerono/Merck. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH/NINDS. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunis Biomedical. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman-La Roche. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for argenx. Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Habib has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jansen/Joohnson & Johnson. The institution of Dr. Habib has received research support from Alexion. The institution of Dr. Habib has received research support from Horizon/Amgen. The institution of Dr. Habib has received research support from Immunovant. The institution of Dr. Habib has received research support from UCB. The institution of Dr. Habib has received research support from argenx. The institution of Dr. Habib has received research support from CabalettaBio. The institution of Dr. Habib has received research support from Regeneron. The institution of Dr. Habib has received research support from Arcellx. The institution of Dr. Habib has received research support from Novartis. The institution of Dr. Habib has received research support from EMDSerono/Merck. The institution of Dr. Habib has received research support from Cour Pharmaceuticals.
	No disclosure on file
Kathy Perez	Kathy Perez has received personal compensation for serving as an employee of argenx. Kathy Perez has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for argenx. Kathy Perez has stock in argenx. Kathy Perez has received personal compensation in the range of $100,000-$499,999 for serving as a VP Global Patient Advocacy with argenx.
Cathleen Bergin	Cathleen Bergin has stock in argenx.
Glenn A. Phillips, PhD	Dr. Phillips has received personal compensation for serving as an employee of argenx. Dr. Phillips has stock in argenx.

��ɫ��

��ɫ��